相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。The glucose-dependent insulinotropic polypeptide (GIP) regulates body weight and food intake via CNS-GIPR signaling
Qian Zhang et al.
CELL METABOLISM (2021)
The Antiresorptive Effect of GIP, But Not GLP-2, Is Preserved in Patients With Hypoparathyroidism-A Randomized Crossover Study
Kirsa Skov-Jeppesen et al.
JOURNAL OF BONE AND MINERAL RESEARCH (2021)
Structural insights into hormone recognition by the human glucose-dependent insulinotropic polypeptide receptor
Fenghui Zhao et al.
ELIFE (2021)
GIP's effect on bone metabolism is reduced by the selective GIP receptor antagonist GIP(3-30)NH2
Laerke S. Gasbjerg et al.
BONE (2020)
GIP and GLP-1 Receptor Antagonism During a Meal in Healthy Individuals
Laerke S. Gasbjerg et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2020)
The Novel Dual GLP-1/GIP Receptor Agonist DA-CH5 Is Superior to Single GLP-1 Receptor Agonists in the MPTP Model of Parkinson?s Disease
Lingyu Zhang et al.
JOURNAL OF PARKINSONS DISEASE (2020)
Tirzepatide is an imbalanced and biased dual GIP and GLP-1 receptor agonist
Francis S. Willard et al.
JCI INSIGHT (2020)
A single unified model for fitting simple to complex receptor response data
Peter Buchwald
SCIENTIFIC REPORTS (2020)
A unique hormonal recognition feature of the human glucagon-like peptide-2 receptor
Wen Sun et al.
CELL RESEARCH (2020)
The role of endogenous GIP and GLP-1 in postprandial bone homeostasis
Mads M. Helsted et al.
BONE (2020)
Separate and Combined Effects of GIP and GLP-1 Infusions on Bone Metabolism in Overweight Men Without Diabetes
Natasha Chidekel Bergmann et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2019)
Gut Hormones and Their Effect on Bone Metabolism. Potential Drug Therapies in Future Osteoporosis Treatment
Sine Paasch Schiellerup et al.
FRONTIERS IN ENDOCRINOLOGY (2019)
Glucagon like peptide 2 has a positive impact on osteoporosis in ovariectomized rats
Bing'er Xu et al.
LIFE SCIENCES (2019)
GLP-2 and GIP exert separate effects on bone turnover: A randomized, placebo-controlled, crossover study in healthy young men
Kirsa Skov-Jeppesen et al.
BONE (2019)
Increased Body Weight and Fat Mass After Subchronic GIP Receptor Antagonist, but Not GLP-2 Receptor Antagonist, Administration in Rats
Sara Baldassano et al.
FRONTIERS IN ENDOCRINOLOGY (2019)
Glucose-Dependent Insulinotropic Polypeptide (GIP) Inhibits Bone Resorption Independently of Insulin and Glycemia
Mikkel B. Christensen et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2018)
Human GIP(3-30)NH2 inhibits G protein-dependent as well as G protein-independent signaling and is selective for the GIP receptor with high-affinity binding to primate but not rodent GIP receptors
Maria Buur Nordskov Gabe et al.
BIOCHEMICAL PHARMACOLOGY (2018)
Chemical Strategies for Half-Life Extension of Biopharmaceuticals: Lipidation and Its Alternatives
Esben M. Bech et al.
ACS MEDICINAL CHEMISTRY LETTERS (2018)
Efficacy and safety of LY3298176, a novel dual GIP and GLP-1 receptor agonist, in patients with type 2 diabetes: a randomised, placebo-controlled and active comparator-controlled phase 2 trial
Juan Pablo Frias et al.
LANCET (2018)
Insulin Secretion Depends on Intra- islet Glucagon Signaling
Berit Svendsen et al.
CELL REPORTS (2018)
Use of bone turnover markers in postmenopausal osteoporosis
Richard Eastell et al.
LANCET DIABETES & ENDOCRINOLOGY (2017)
New horizons in treatment of osteoporosis
Ozra Tabatabaei-Malazy et al.
DARU-JOURNAL OF PHARMACEUTICAL SCIENCES (2017)
Species-specific action of (Pro3)GIP - a full agonist at human GIP receptors, but a partial agonist and competitive antagonist at rat and mouse GIP receptors
A. H. Sparre-Ulrich et al.
BRITISH JOURNAL OF PHARMACOLOGY (2016)
Direct effect of incretin hormones on glucose and glycerol metabolism and hemodynamics
Kristian Karstoft et al.
AMERICAN JOURNAL OF PHYSIOLOGY-ENDOCRINOLOGY AND METABOLISM (2015)
A rationally designed monomeric peptide triagonist corrects obesity and diabetes in rodents
Brian Finan et al.
NATURE MEDICINE (2015)
Glucose-Dependent Insulinotropic Polypeptide Inhibits Bone Resorption in Humans
Anne Nissen et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2014)
A Functional Amino Acid Substitution in the Glucose-Dependent Insulinotropic Polypeptide Receptor (GIPR) Gene Is Associated With Lower Bone Mineral Density and Increased Fracture Risk
S. S. Torekov et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2014)
A Naturally Occurring GIP Receptor Variant Undergoes Enhanced Agonist-Induced Desensitization, Which Impairs GIP Control of Adipose Insulin Sensitivity
Sameer Mohammad et al.
MOLECULAR AND CELLULAR BIOLOGY (2014)
A Novel Humanized GLP-1 Receptor Model Enables Both Affinity Purification and Cre-LoxP Deletion of the Receptor
Lucy S. Jun et al.
PLOS ONE (2014)
A novel truncated glucagon-like peptide 2 (GLP-2) as a tool for analyzing GLP-2 receptor agonists
Kazuto Yamazaki et al.
BIOMEDICAL RESEARCH-TOKYO (2013)
Glucose-dependent insulinotropic polypeptide receptor deficiency leads to modifications of trabecular bone volume and quality in mice
Christine Gaudin-Audrain et al.
BONE (2013)
Pharmacokinetics and Pharmacokinetic-Pharmacodynamic Correlations of Therapeutic Peptides
Lei Diao et al.
CLINICAL PHARMACOKINETICS (2013)
Effect of glucagon-like peptide-2 exposure on bone resorption: Effectiveness of high concentration versus prolonged exposure
Carsten Askov-Hansen et al.
REGULATORY PEPTIDES (2013)
Unimolecular Dual Incretins Maximize Metabolic Benefits in Rodents, Monkeys, and Humans
Brian Finan et al.
SCIENCE TRANSLATIONAL MEDICINE (2013)
Osteoporosis in the European Union: medical management, epidemiology and economic burden
E. Hernlund et al.
ARCHIVES OF OSTEOPOROSIS (2013)
Xenin-25 increases cytosolic free calcium levels and acetylcholine release from a subset of myenteric neurons
Sheng Zhang et al.
AMERICAN JOURNAL OF PHYSIOLOGY-GASTROINTESTINAL AND LIVER PHYSIOLOGY (2012)
The comparative gastrointestinal tolerability of proprietary versus generic alendronate in patients treated for primary osteoporosis
Erik Landfeldt et al.
BONE (2012)
The Family B1 GPCR: Structural Aspects and Interaction with Accessory Proteins
Alain Couvineau et al.
CURRENT DRUG TARGETS (2012)
Glucagon-like peptide-1 (GLP-1) receptor agonism or DPP-4 inhibition does not accelerate neoplasia in carcinogen treated mice
Hannelouise Kissow et al.
REGULATORY PEPTIDES (2012)
Conformational, receptor interaction and alanine scan studies of glucose-dependent insulinotropic polypeptide
Kalyana C. Venneti et al.
BIOCHIMICA ET BIOPHYSICA ACTA-PROTEINS AND PROTEOMICS (2011)
Conformational and molecular interaction studies of glucagon-like peptide-2 with its N-terminal extracellular receptor domain
Kalyana C. Venneti et al.
FEBS LETTERS (2011)
Cellular and Molecular Mechanisms of Bone Remodeling
Liza J. Raggatt et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2010)
Identification of Determinants of Glucose-Dependent Insulinotropic Polypeptide Receptor That Interact with N-Terminal Biologically Active Region of the Natural Ligand
Tahir Yaqub et al.
MOLECULAR PHARMACOLOGY (2010)
Four-month treatment with GLP-2 significantly increases hip BMD A randomized, placebo-controlled, dose-ranging study in postmenopausal women with low BMD
Dennis B. Henriksen et al.
BONE (2009)
A new glucagon and GLP-1 co-agonist eliminates obesity in rodents
Jonathan W. Day et al.
NATURE CHEMICAL BIOLOGY (2009)
Bisphosphonates: Mechanism of action and role in clinical practice
Mathew T. Drake et al.
MAYO CLINIC PROCEEDINGS (2008)
Reduction in bone resorption by exogenous glucagon-like peptide-2 administration requires an intact gastrointestinal tract
Ida B. Gottschalck et al.
SCANDINAVIAN JOURNAL OF GASTROENTEROLOGY (2008)
Crystal structure of the incretin-bound extracellular domain of a G protein-coupled receptor
Christoph Parthier et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2007)
Oxyntomodulin differentially affects glucagon-like peptide-1 receptor β-arrestin recruitment and signaling through Gαs
Rasmus Jorgensen et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2007)
Understanding interactions of gastric inhibitory polypeptide (GIP) with its G-protein coupled receptor through NMR and molecular modeling
Alpeshkumar K. Malde et al.
JOURNAL OF PEPTIDE SCIENCE (2007)
Disassociation of bone resorption and formation by GLP-2 - A 14-day study in healthy postmenopausal women
Dennis B. Henriksen et al.
BONE (2007)
The elimination rates of intact GIP as well as its primary metabolite, GIP 3-42, are similar in type 2 diabetic patients and healthy subjects
Tina Vilsboll et al.
REGULATORY PEPTIDES (2006)
Gastric inhibitory polypeptide as an endogenous factor promoting new bone formation after food ingestion
Katsushi Tsukiyama et al.
MOLECULAR ENDOCRINOLOGY (2006)
Impaired intestinal proglucagon processing in mice lacking prohormone convertase 1
R Ugleholdt et al.
ENDOCRINOLOGY (2004)
Reduction of nocturnal rise in bone resorption by subcutaneous GLP-2
DB Henriksen et al.
BONE (2004)
Role of gastrointestinal hormones in postprandial reduction of bone resorption
DB Henriksen et al.
JOURNAL OF BONE AND MINERAL RESEARCH (2003)
Octreotide abolishes the acute decrease in bone turnover in response to oral glucose
JA Clowes et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2003)
Structure-function analysis of a series of novel GIP analogues containing different helical length linkers
S Manhart et al.
BIOCHEMISTRY (2003)
Structural determinants for activity of glucagon-like peptide-2
MP DaCambra et al.
BIOCHEMISTRY (2000)
Long-term risk of osteoporotic fracture in Malmo
JA Kanis et al.
OSTEOPOROSIS INTERNATIONAL (2000)
分享论文
